Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous AZD1305 for cardioversion of atrial fibrillation
2009-009862-15Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Mar 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Atrial fibrillation (AFib) comparing AZD1305 intravenous dose-escalation with Intravenous placebo (2 arms). Primary endpoint: Heart rhythm conversion to sinus rhythm within 90 minutes. Started Mar 2009; status: terminated.
02
Drugs
AZD-1305
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2009-009862-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009862-15.